Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Accounts Payables: 2019-2024

Historic Accounts Payables for Beam Therapeutics (BEAM) over the last 6 years, with Dec 2024 value amounting to $3.9 million.

  • Beam Therapeutics' Accounts Payables rose 150.39% to $9.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.5 million, marking a year-over-year increase of 150.39%. This contributed to the annual value of $3.9 million for FY2024, which is 139.39% up from last year.
  • As of FY2024, Beam Therapeutics' Accounts Payables stood at $3.9 million, which was up 139.39% from $1.6 million recorded in FY2023.
  • Beam Therapeutics' 5-year Accounts Payables high stood at $9.0 million for FY2022, and its period low was $1.6 million during FY2023.
  • Its 3-year average for Accounts Payables is $4.8 million, with a median of $3.9 million in 2024.
  • In the last 5 years, Beam Therapeutics' Accounts Payables crashed by 82.09% in 2023 and then soared by 139.39% in 2024.
  • Yearly analysis of 5 years shows Beam Therapeutics' Accounts Payables stood at $6.3 million in 2020, then climbed by 18.37% to $7.5 million in 2021, then climbed by 20.81% to $9.0 million in 2022, then crashed by 82.09% to $1.6 million in 2023, then skyrocketed by 139.39% to $3.9 million in 2024.